News
Novo Nordisk beats on Q1 earnings, cuts 2025 outlook
Novo reported $11.9 billion in revenues, in line with Wall Street's estimates, and beat on adjusted earnings per share (EPS) with 99 cents per share compared to estimates of 94 cents per share. Sales of the company's blockbuster GLP-1 drugs, up 13% year-over-year, drove the quarter's results, despite a slight slowdown in weight loss sales.
Shares rallied Wednesday even after the drugmaker lowered its full-year guidance as alternative versions of its blockbuster ...
6don MSN
CVS Health said it will significantly expand access to Novo Nordisk's blockbuster weight loss drug Wegovy for patients ...
Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access ...
GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...
A new executive order aims to smooth the path for getting U.S. manufacturing facilities up and running; HHS says it will ...
The obesity drug price wars are finally starting. After being publicly lambasted for the high cost of their weight-loss shots ...
Wegovy was first to market but has been losing ground to Eli Lilly's Zepbound in recent months, according to the latest ...
Eli Lilly shares dropped Thursday as Novo Nordisk notched a coverage win for its obesity drug, a sign of the competition in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback